GlassScriptPhysician profile
Surekha Collur
NPI 1750491015
$5,963.04
in general payments reported to CMS, 2019-2025
32 companies · $1,109 in 2025
The $1,109 reported for 2025 was more than what 80% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $358 · 2020: $325 · 2021: $788 · 2022: $591 · 2023: $2,032 · 2024: $759 · 2025: $1,109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,849 · Debt Forgiveness: $26.14 · Education: $25.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,848.79 |
| Debt Forgiveness | $26.14 |
| Education | $25.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,113.53 | 2022-2025 | Durysta, Xen Glaucoma Treatment System, Lumigan |
| Allergan, INC. | $600.89 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $596.80 | 2019-2025 | Cequa |
| Alcon Vision LLC | $577.74 | 2020-2025 | Rocklatan, Rhopressa, Tryptyr |
| Bausch & Lomb Americas INC. | $446.22 | 2022-2025 | Envista Mx60 Iol, Miebo, Xiidra |
| Glaukos Corporation | $317.98 | 2023-2025 | Istent Inject Trabecular Micro-Bypass System Model G2-M-Is |
| Biotissue Holdings INC. | $251.11 | 2022-2025 | |
| Nova Eye, INC. | $233.58 | 2023 | |
| Sight Sciences, INC. | $188.19 | 2019-2025 | Omni Surgical System, Sion Surgical Instrument |
| Johnson & Johnson Surgical Vision, INC. | $170.06 | 2021 | |
| Oyster Point Pharma, INC. | $164.58 | 2022-2025 | Tyrvaya, Ryzumvi |
| Rxsight INC | $132.03 | 2023 | Rxsight Light Adjustable Lens (Rxlal), Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Horizon Therapeutics Plc | $124.67 | 2023 | Tepezza |
| Novartis Pharmaceuticals Corporation | $119.63 | 2019-2022 | |
| Apellis Pharmaceuticals, INC. | $114.56 | 2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $106.98 | 2019-2022 | |
| Aerie Pharmaceuticals, INC. | $98.80 | 2019-2021 | |
| Dompe US, INC. | $86.45 | 2024-2025 | Oxervate |
| Harrow Eye, LLC | $67.31 | 2024-2025 | Vevye |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $55.30 | 2019-2021 | |
| Carl Zeiss Meditec, INC. | $53.35 | 2020-2023 | |
| Thea Pharma INC. | $51.48 | 2024-2025 | Iyuzeh |
| New World Medical,INC. | $46.36 | 2024-2025 | Streamline, Ahmed Glaucoma Valve, Kahook Dual Blade |
| Eyevance Pharmaceuticals LLC | $45.60 | 2020-2022 | |
| Coopervision INC. | $37.94 | 2019-2025 | Clariti Contact Lens |
| Tarsus Pharmaceuticals, INC. | $35.31 | 2024-2025 | Xdemvy |
| Eyepoint US, INC. | $29.04 | 2019 | |
| Quidel Corporation | $26.14 | 2023 | |
| Beaver-Visitec International, INC. | $22.81 | 2021 | |
| Amgen INC. | $19.20 | 2024 | Tepezza |
| Ocular Therapeutix, INC. | $14.80 | 2022 | |
| Shire North American Group INC | $14.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Surekha Collur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.